ArticleThe journal of nutrition, health & aging2009
Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.
Article in The journal of nutrition, health & aging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Implications of Microorganisms in Alzheimer's Disease.Current issues in molecular biology · 2022Review
- Therapeutic strategies for tauopathies and drug repurposing as a potential approach.Biochemical pharmacology · 2022Review
- Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.Nature reviews. Neurology · 2018Review
- Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease.Molecules (Basel, Switzerland) · 2017Review
- NPT088 reduces both amyloid-β and tau pathologies in transgenic mice.Alzheimer's & dementia (New York, N. Y.) · 2016Article
- The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy.Molecular neurobiology · 2016Review
- Inhibition of Both Hsp70 Activity and Tau Aggregation in Vitro Best Predicts Tau Lowering Activity of Small Molecules.ACS chemical biology · 2016Article
- Untangling tau imaging.Alzheimer's & dementia (Amsterdam, Netherlands) · 2016Review
- Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies.Scientific reports · 2015Article
- Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography.PloS one · 2015Article
- Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.PloS one · 2015Article
- Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke.Brain research · 2014Article
- Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.CNS drugs · 2014Review
- Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.The Journal of biological chemistry · 2014Article
- Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography.Journal of Alzheimer's disease & Parkinsonism · 2014Article
- New Treatment for Alzheimer's Disease, Kamikihito, Reverses Amyloid-β-Induced Progression of Tau Phosphorylation and Axonal Atrophy.Evidence-based complementary and alternative medicine : eCAM · 2014Article
- Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.CNS & neurological disorders drug targets · 2014Article
- Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.Alzheimer's research & therapy · 2014Article
- Alzheimer disease therapy--moving from amyloid-β to tau.Nature reviews. Neurology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.